These discoveries suggest the significant role of NLRP3 inflammasome in the pathogenesis of AD and, more importantly, indicate that patients with AD may benefit from therapeutic strategies targeting NLRP3 inflammasome. This evidence concerns the gene NLRP3 and Alzheimer disease.